Clinical Trials

Phase 2 Not yet recruiting

Advanced Solid Tumor

NCT07450976 2026-03-12

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

151 enrolled

Biliary Tract Neoplasms

NCT07111546 2026-03-11

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

140 enrolled

Advanced Solid Tumour

NCT06821503 2026-03-10

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

72 enrolled

Advanced Pancreatic Cancer

NCT06765590 2026-03-09

Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

Phase NA Recruiting

24 enrolled

Breast

Breast Neoplasms

NCT07069062 2026-03-09

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors

261 enrolled

Solid Tumor

NCT07331155 2026-03-09

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

110 enrolled

Phase 3 Active not recruiting

Advanced Solid Tumour

NCT05184712 2026-03-04

Phase 3 Clinical Study of AK112 for NSCLC Patients

322 enrolled

Phase 2 Not yet recruiting

Non-Squamous Non-small Cell Lung Cancer

NCT07448922 2026-03-04

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

290 enrolled

Advanced Gynecological Malignancies

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

Phase 1 Not yet recruiting

218 enrolled

Genitourinary

Prostatic Neoplasms

NCT07434609 2026-02-25

Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

150 enrolled

Phase 3 Not yet recruiting

Advanced Solid Tumor (Phase 1)

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04752826 2026-02-18

MK-3475-D20

DermatologicGynecologicLymphoid

176 enrolled

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT07418749 2026-02-18

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Phase 3 Not yet recruiting

398 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07409428 2026-02-13

A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

Phase 3 Not yet recruiting

240 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06783647 2026-02-12

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

230 enrolled

Advanced Solid Tumour

NCT06956001 2026-02-12

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

380 enrolled

NSCLC Patients With Brain Metastasis

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

220 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06752811 2026-02-10

pompom

416 enrolled

Pancreatic Cancer Metastatic

NCT05620017 2026-02-09

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

182 enrolled

Phase 2 Not yet recruiting

Advanced Solid Tumors

NCT07390383 2026-02-09

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

110 enrolled

Advanced Solid Tumour

NCT07398339 2026-02-09

DVDMS

30 enrolled

Biliary Tract Neoplasms

NCT06580301 2026-02-06

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

46 enrolled

Lymphoid

Burkitt Lymphoma

NCT07230405 2026-02-06

A Phase II Study of SKB571 in Patients With Lung Cancer

190 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06565689 2026-02-05

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

48 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

70 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05020236 2026-02-02

MAGNETISMM-5

944 enrolled

Plasma cell

Multiple Myeloma

NCT07196774 2026-01-30

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

740 enrolled

Breast

Early-stage or Locally Advanced HER2-positive Breast Cancer

NCT06792552 2026-01-29

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

414 enrolled

Advanced Solid Tumors

NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

604 enrolled

Phase 2 Active not recruiting

Advanced Biliary Tract Cancer

NCT05816252 2026-01-27

MK-2870-003

356 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

EndocrineGastrointestinalGenitourinaryNET

27 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT07112222 2026-01-26

A Study of LM-350 in Subjects With Advanced Solid Tumours

Phase 1/2 Not yet recruiting

80 enrolled

Tumor-Agnostic

Neoplasms

NCT07367529 2026-01-26

A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

465 enrolled

Advanced Lung Cancer

NCT07368478 2026-01-26

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

180 enrolled

Advanced Solid Malignancies

NCT07348211 2026-01-23

SIM0610-101

GastrointestinalHead & NeckThoracic

260 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT07110571 2026-01-09

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

200 enrolled

Stomach Neoplasms

NCT04284488 2026-01-08

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Phase 1/2 Terminated

40 enrolled

Advanced Solid Tumor

NCT04643405 2026-01-08

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Phase 1/2 Terminated

21 enrolled

Phase 1/2 Not yet recruiting

Pancreatic Neoplasms

NCT07326488 2026-01-08

A Study of MHB009C in Patients With Advanced Solid Tumors

200 enrolled

Advanced Malignant Solid Tumor

NCT04175847 2026-01-07

A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Phase 1/2 Completed

198 enrolled

Solid Tumor

NCT06173037 2026-01-07

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Phase 2 Completed

43 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06298058 2026-01-07

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

144 enrolled

Phase 2/3 Not yet recruiting

Advanced Solid Tumor

NCT06545617 2026-01-07

A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

Phase 1/2 Withdrawn

Gynecologic

Fallopian Tube Neoplasms

NCT07321847 2026-01-07

INJECTABL-3

717 enrolled

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04617314 2026-01-06

A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors

Phase 1 Completed

67 enrolled

Solid Tumor

NCT06482905 2026-01-06

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.